Dopamine-receptor agonists





Indications

  • Parkinson's disease
  • Prolactinoma/galactorrhoea
  • Cyclical breast disease
  • Acromegaly

Adverse effects

Ergot-derived dopamine receptor agonists (bromocriptine, cabergoline, pergolide*) have been associated with pulmonary, retroperitoneal and cardiac fibrosis. The Committee on Safety of Medicines advice that an ESR, creatinine and chest x-ray should be obtained prior to treatment and patients should be closely monitored

  • Nausea/vomiting
  • Postural hypotension
  • Hallucinations
  • Daytime somnolence

*pergolide was withdrawn from the US market in March 2007 due to concern regarding increased incidence of valvular dysfunction